Infliximab therapy in parenchymal neuro-Behçet's disease: A single-center experience.

Background Parenchymal neuro-Behcet's disease involvement is the most serious complication of Behcet's disease, and no sufficient data on its treatment exists. This study aims to investigate the efficacy and safety of infliximab treatment in neuro-Behcet's disease patients with parenchymal involvement. Materials and methods Patients who were diagnosed with Behcet's disease with parenchymal neurological involvement and underwent infliximab treatment for at least 12 months were included in the study. Demographic, clinical, and radiological data of the patients were accessed through the electronic database of our hospital. Results This study comprises 19 patients who were diagnosed with neuro-Behcet's disease and used infliximab: 12 male and 7 female patients. The mean age of the patients was 36.5 ± 11.7 years, and the diagnostic age was 26.3 ± 10.8 years. The duration of treatment with infliximab was 32.3 months (minimum 11, max 79). In the 19 patients receiving infliximab treatment, 11 (58%) patients achieved remission (complete disappearance of neurological symptoms) and 7 (37%) patients achieved disease stability (no new neurological findings); steroid treatments were discontinued for these 18 patients. In addition, only 5 patients were concomitantly taking immunosuppressive drugs with the infliximab. Infliximab was discontinued after the development of a new parenchymal attack in the 9th month of infliximab treatment. Conclusion In conclusion, parenchymal neurological involvement in Behcet's disease is an important cause of disability, and no sufficient data exists in literature on its treatment. The results of our study suggest that infliximab treatment was effective and safe in neuro-Behcet's disease parenchymal involvement for preventing long-term neurological attacks and discontinuing corticosteroid treatment.